Johnson & Johnson Invests $14.6B in Intra-Cellular to Advance CNS Disorder Treatments
Johnson & Johnson Expands Neuroscience Portfolio
Johnson & Johnson has announced a significant investment of over $14 billion to enhance its focus on central nervous system disorders. This strategic move involves the acquisition of Intra-Cellular Therapies, a company renowned for its innovative treatments. By integrating Intra-Cellular Therapies into its operations, Johnson & Johnson aims to strengthen its position in the healthcare sector and drive advancements in mental health treatments.
Financial Details of the Deal
The healthcare giant will acquire Intra-Cellular Therapies at a price of $132 per share in cash. This offer represents a 39% premium over Intra-Cellular’s closing stock price of $94.87. The total value of the deal is estimated at approximately $14.6 billion, which Johnson & Johnson plans to finance through a combination of cash and debt.
Market Reaction and Share Performance
Following the announcement, shares of both Johnson & Johnson and Intra-Cellular Therapies saw a positive surge. Intra-Cellular’s stock price jumped about 34% to $127.10, reflecting investor confidence in the deal. Meanwhile, Johnson & Johnson’s stock experienced a modest increase of 1%, reaching $143.45.
Intra-Cellular Therapies' Leading Products
Intra-Cellular Therapies is best known for Caplyta, a once-daily pill designed to treat adults with schizophrenia and depression associated with bipolar disorder. The drug generated $175 million in revenue during the third quarter of last year, with prescriptions rising by 38%. The company is also seeking FDA approval to use Caplyta as a supplemental treatment for major depressive disorder, signaling potential for broader market reach.
Growth Prospects and Pipeline Developments
Wall Street analysts from FactSet predict that sales of Caplyta will surpass $1 billion next year and could exceed $2.5 billion by 2028. In addition to Caplyta, Intra-Cellular Therapies has a promising pipeline of drugs under development. This includes treatments for anxiety, psychosis, and agitation related to Alzheimer’s disease, with some candidates currently in mid-stage testing.
Conclusion
Johnson & Johnson's acquisition of Intra-Cellular Therapies marks a major step in expanding its capabilities in treating central nervous system disorders. With a robust portfolio of existing products and a strong pipeline of future treatments, the deal is poised to drive significant growth and innovation in the mental health sector. Both companies are optimistic about the merger, expecting the deal to close later this year pending regulatory approvals.
Read the full article here:
clickondetroit.com